Search
Yunnan Baiyao's Yunhe Pharmaceutical Secures Approval for Drug Clinical Trials of INR102 Injection
2025-04-08 /
Read about 0 minute
Author：小编
Yunnan Baiyao's wholly-owned subsidiary, Yunhe Pharmaceutical, has recently secured approval from the National Medical Products Administration to initiate clinical trials for its Class 1 innovative chemical drug, INR102 Injection, specifically designed for prostate cancer. This groundbreaking medication is intended for patients diagnosed with metastatic castration-resistant prostate cancer who have undergone specific chemotherapy regimens. To date, approximately RMB 23.325 million has been dedicated to research and development expenses for this promising treatment.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
